Sei Investments Co. Grows Stock Position in Haleon PLC Sponsored ADR $HLN

Sei Investments Co. increased its holdings in Haleon PLC Sponsored ADR (NYSE:HLN) by 89.4% during the 1st quarter, Holdings Channel.com reports. The institutional investor owned 1,285,485 shares of the company’s stock after purchasing an additional 606,864 shares during the quarter. Sei Investments Co.’s holdings in Haleon were worth $12,867,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Lido Advisors LLC increased its holdings in Haleon by 22.5% during the 1st quarter. Lido Advisors LLC now owns 59,908 shares of the company’s stock valued at $600,000 after acquiring an additional 11,009 shares in the last quarter. Cetera Investment Advisers lifted its holdings in shares of Haleon by 17.0% in the first quarter. Cetera Investment Advisers now owns 247,741 shares of the company’s stock valued at $2,480,000 after purchasing an additional 36,006 shares in the last quarter. WCM Investment Management LLC lifted its holdings in shares of Haleon by 70.3% in the first quarter. WCM Investment Management LLC now owns 1,725,059 shares of the company’s stock valued at $17,251,000 after purchasing an additional 711,817 shares in the last quarter. Parallel Advisors LLC grew its position in shares of Haleon by 20.4% in the first quarter. Parallel Advisors LLC now owns 30,272 shares of the company’s stock valued at $303,000 after purchasing an additional 5,134 shares during the last quarter. Finally, Annis Gardner Whiting Capital Advisors LLC grew its position in shares of Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after purchasing an additional 2,404 shares during the last quarter. 6.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HLN has been the subject of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research note on Thursday, April 30th. Wall Street Zen upgraded Haleon from a “hold” rating to a “buy” rating in a report on Sunday, July 12th. Rothschild & Co Redburn cut Haleon from a “strong-buy” rating to a “hold” rating in a report on Tuesday, June 16th. Weiss Ratings reissued a “hold (c)” rating on shares of Haleon in a research report on Tuesday, June 30th. Finally, Zacks Research downgraded Haleon from a “hold” rating to a “strong sell” rating in a research report on Tuesday, July 21st. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have given a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Haleon currently has an average rating of “Moderate Buy”.

Haleon Stock Performance

Shares of HLN opened at $9.87 on Friday. Haleon PLC Sponsored ADR has a 1 year low of $8.65 and a 1 year high of $11.28. The company’s 50 day simple moving average is $9.44 and its 200 day simple moving average is $9.85. The company has a market capitalization of $43.45 billion, a price-to-earnings ratio of 25.29, a PEG ratio of 2.34 and a beta of 0.13. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.71 and a current ratio of 0.92.

Haleon Cuts Dividend

The firm also recently declared a dividend, which will be paid on Thursday, September 17th. Shareholders of record on Friday, August 14th will be paid a dividend of $0.0642 per share. This represents a dividend yield of 127.0%. The ex-dividend date of this dividend is Friday, August 14th. Haleon’s dividend payout ratio is currently 64.10%.

Haleon Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over?the?counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self?care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.